Evidence map›Paper›PMID 37653182›Full record

ArticleStem cell reviews and reports2023

Using Ribonucleoprotein-based CRISPR/Cas9 to Edit Single Nucleotide on Human Induced Pluripotent Stem Cells to Model Type 3 Long QT Syndrome (SCN5A

Ning Ge, Min Liu, Rui Li, Nicholas M Allen, Joseph Galvin, Sanbing Shen, Timothy O'Brien, Terence W Prendiville

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell reviews and reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Ning GeRegenerative Medicine Institute, School of Medicine, College of Medicine, Nursing and Health Science, University of Galway, Galway, Ireland.
Min LiuDepartment of Physiology, College of Life Science, Hebei Normal University, Shijiazhuang, China.
Rui LiLambe Institute for Translational Research, University of Galway, Galway, Ireland.
Nicholas M AllenRegenerative Medicine Institute, School of Medicine, College of Medicine, Nursing and Health Science, University of Galway, Galway, Ireland.
Joseph GalvinMater Misericordiae University Hospital, Eccles St., Dublin 7, Ireland.
Sanbing ShenRegenerative Medicine Institute, School of Medicine, College of Medicine, Nursing and Health Science, University of Galway, Galway, Ireland.
Timothy O'BrienRegenerative Medicine Institute, School of Medicine, College of Medicine, Nursing and Health Science, University of Galway, Galway, Ireland.
Terence W PrendivilleRegenerative Medicine Institute, School of Medicine, College of Medicine, Nursing and Health Science, University of Galway, Galway, Ireland. Terence.Prendiville@olchc.ie.ORCID 0000-0002-3824-636X
Ollscoil na Gaillimhe – University of Galway · IEHebei Normal University · CNMater Misericordiae University Hospital · IENorthwestern University · USRoyal College of Surgeons in Ireland · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human induced pluripotent stem cells (hiPSCs) have been widely used in cardiac disease modelling, drug discovery, and regenerative medicine as they can be differentiated into patient-specific cardiomyocytes. Long QT syndrome type 3 (LQT3) is one of the more malignant congenital long QT syndrome (LQTS) variants with an SCN5A gain-of-function effect on the gated sodium channel. Moreover, the predominant pathogenic variants in LQTS genes are single nucleotide substitutions (missense) and small insertion/deletions (INDEL). CRISPR/Cas9 genome editing has been utilised to create isogenic hiPSCs to control for an identical genetic background and to isolate the pathogenicity of a single nucleotide change. In this study, we described an optimized and rapid protocol to introduce a heterozygous LQT3-specific variant into healthy control hiPSCs using ribonucleoprotein (RNP) and single-stranded oligonucleotide (ssODN). Based on this protocol, we successfully screened hiPSCs carrying a heterozygous LQT3 pathogenic variant (SCN5A

Indexed as

Induced Pluripotent Stem CellsLong QT SyndromeCRISPR-Cas SystemsHumansNAV1.5 Voltage-Gated Sodium ChannelNucleotidesNAV1.5 Voltage-Gated Sodium ChannelNucleotidesSCN5A protein, humanCRISPR/Cas9Disease modellingElectroporationInduced pluripotent stem cellsLong QT syndrome

Identifiers

PMID37653182
PMCPMC10661835
OpenAlexW4386316460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.